Etosalamide

CAS No. 15302-15-5

Etosalamide ( Ethosalamide )

Catalog No. M20168 CAS No. 15302-15-5

Etosalamide is an antipyretic and analgesics agent.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
10MG 42 In Stock
25MG 68 In Stock
50MG 101 In Stock
100MG 149 In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    Etosalamide
  • Note
    Research use only not for human use.
  • Brief Description
    Etosalamide is an antipyretic and analgesics agent.
  • Description
    Etosalamide is an antipyretic and analgesics agent.
  • Synonyms
    Ethosalamide
  • Pathway
    Others
  • Target
    Other Targets
  • Recptor
    Others
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    15302-15-5
  • Formula Weight
    209.24
  • Molecular Formula
    C11H15NO3
  • Purity
    >98% (HPLC)
  • Solubility
    DMSO:300 mg/mL?(1433.76 mM)
  • SMILES
    CCOCCOc1ccccc1C(N)=O
  • Chemical Name
    o-(2-Ethoxyethoxy)benzamide

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

molnova catalog
related products
  • Somatostatin Acetate

    Somatostatin (GHIH), a peptide hormone, regulates the endocrine system and affects neural transmission and cell proliferation by interacting with G-protein-coupled somatostatin receptors and inhibiting the release of multiple secondary hormones. Somatostatin inhibits secretion of insulin and glucagon.

  • Eptifibatide acetate

    Eptifibatide an antiplatelet drug of the glycoprotein IIb/IIIa inhibitor class is a cyclic heptapeptide constructed from 6 amino acids and a mercaptopropionyl residue.

  • 8-Prenylkaempferol

    8-Prenylkaempferol is an effective agent for attenuating pro-inflammatory NO induction, it may be an anti-inflammatory agent for suppressing influenza A virus-induced RANTES production acts by blocking PI3K-mediated transcriptional activation of NF-κB and IRF-3 and in part by interfering with IκB degradation which subsequently decreases NF-κB translocation.